Sammy Karam - Feb 17, 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
SENIOR VICE PRESIDENT
Signature
/s/ Sammy Karam by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Feb 17, 2023
Transactions value $
$0
Form type
4
Date filed
2/22/2023, 05:58 PM
Previous filing
Jan 3, 2023
Next filing
Mar 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +45.8K $0.00 45.8K Feb 17, 2023 Common Shares 45.8K $106.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,270 on February 17, 2024, 15,271 on February 17, 2025, and 15,271 on February 17, 2026.